

3/1/2022

Medicare Part D Formulary Change

The product changes noted below will be implemented on the Medicare Part D Plan:

New Added Products: **Effective 3/1/2022**

Drug	Reason	Cost sharing**	Restrictions***
BESREMI 500 MCG/ML SUBCUTANEOUS SYRINGE	New Drug	Tier 5	PA LA
DUPIXENT 100 MG/0.67 ML SUBCUTANEOUS SYRINGE	New Drug	Tier 5	PA
EPCLUSA 150 MG-37.5 MG ORAL PELLETS IN PACKET	New Drug	Tier 5	PA QL
EPCLUSA 200 MG-50 MG ORAL PELLETS IN PACKET	New Drug	Tier 5	PA QL
EPRONTIA 25 MG/ML ORAL SOLUTION	New Drug	Tier 4	PA
everolimus (immunosuppressive) 1 mg tablet	New Drug	Tier 5	PA
EXKIVITY 40 MG CAPSULE	New Drug	Tier 5	PA LA
naloxone 4 mg/actuation nasal spray	New Drug	Tier 3	
nylia 1/35 (28) 1 mg-35 mcg tablet	New Drug	Tier 4	
SCSEMBLIX 20 MG TABLET	New Drug	Tier 5	PA QL
SCSEMBLIX 40 MG TABLET	New Drug	Tier 5	PA QL
TICOVAC 2.4 MCG/0.5 ML INTRAMUSCULAR SYRINGE	New Drug	Tier 3	

Future Removed Products: **There are no future removed products this month.**

Cost Sharing Tier Changes: **There were no cost sharing tier changes this month.**

Mutual of Omaha Rx Premier: 22021

*Consult your Medical provider for changes or recommendations to your medical care and prescription therapy

**Please consult the plan benefit design for copay/coinsurance amounts

***Indicates a restriction of Step Therapy, Prior Authorization or Quantity Limits may exist [LA] = Limited Access, [PA] = Prior Authorization, [QL] = Quantity Limit, [ST] = Step Therapy